Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab.

Trial Profile

Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 06 Feb 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top